OOIR: Observatory of International Research

Papers

(The median citation count of Best Practice & Research Clinical Endocrinology & Metabolism is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma	96
Gut microbiome, prebiotics, intestinal permeability and diabetes complications	60
Next-generation therapies for adrenocortical carcinoma	57
Cushing's syndrome: Overview of clinical presentation, diagnostic tools and complications	53
Menopausal hormone therapy for the management of osteoporosis	53
Gut microbiome and bile acids in obesity-related diseases	52
New perspectives for mitotane treatment of adrenocortical carcinoma	46
Epidemiology and mortality of Cushing’s syndrome	45
Intestinal microbiota and diabetic kidney diseases: the Role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression	42
Gut microbiome and thyroid autoimmunity	38
Adrenocortical tumorigenesis: Lessons from genetics	36
Pheochromocytoma: An approach to diagnosis	35
TPO antibody positivity and adverse pregnancy outcomes	35
Genetic underpinnings of asthenozoospermia	35
Genetics of ovarian insufficiency and defects of folliculogenesis	34
Exposure to endocrine-disrupting compounds such as phthalates and bisphenol A is associated with an increased risk for obesity	31
Cushing's syndrome: Treatment and new therapeutic approaches	31
Impact of thyroid disease on fertility and assisted conception	30
Basics of androgen synthesis and action	29
Genetics of teratozoospermia: Back to the head	29
Hormone therapy regimens for managing the menopause and premature ovarian insufficiency	29
Pediatric adrenocortical tumours	29
Adrenocortical hyperplasia: A multifaceted disease	29
Iodine status and supplementation before, during, and after pregnancy	28
Endocrine-disrupting chemicals and their effects on puberty	28

Diagnosis and differential diagnosis of diabetes insipidus: Update	28
Genetic mutations contributing to non-obstructive azoospermia	26
Endocrine disruptors and the male reproductive system	25
Central diabetes insipidus in children: Diagnosis and management	25
Prevalence, diagnosis and outcomes of treatment for primary aldosteronism	24
Menopausal hormone therapy and breast cancer risk	24
Metastatic pheochromocytoma and paraganglioma: Management of endocrine manifestations, surgery and ablative procedures, and systemic therapies	24
Management of central diabetes insipidus	24
Immune checkpoint inhibitor-related thyroid dysfunction	23
Updates in adrenal steroidogenesis inhibitors for Cushing’s syndrome – A practical guide	23
Acquired forms of central diabetes insipidus: Mechanisms of disease	23
Bone marrow adiposity and the hematopoietic niche: A historical perspective of reciprocity, heterogeneity, and lineage commitment	23
Phthalates, ovarian function and fertility in adulthood	22
Role of unilateral adrenalectomy in bilateral adrenal hyperplasias with Cushing’s syndrome	22
Controversies and advances in adrenal venous sampling in the diagnostic workup of primary aldosteronism	21
Acquisition of peak bone mass	21
Thyroid hormone system disrupting chemicals	20
Universal screening for thyroid disease during pregnancy should be performed	20
Endocrine-disrupting chemicals and child health	20
Cardiovascular complications of mild autonomous cortisol secretion	20
Surgery for adrenocortical carcinoma: When and how?	20
The gut microbiota as a versatile immunomodulator in obesity and associated metabolic disorders	20
Gut microbiota and metabolic aspects of cancer cachexia	19
Gestational diabetes insipidus: Diagnosis and management	18
Bone marrow adipose tissue: Role in bone remodeling and energy metabolism	18
Perinatal exposure to endocrine disrupting chemicals and neurodevelopment: How articles of daily use influence the development of our children	18
Indications for treatment of subclinical hypothyroidism and isolated hypothyroxinaemia in pregnancy	18
Endocrine disrupting chemicals and bone	17
Osteopathy in mild adrenal Cushing’s syndrome and Cushing disease	17
Genetics and epigenetics of autoimmune thyroid diseases: Translational implications	17
Management of thyrotoxicosis during pregnancy	17
The spectrum of low-renin hypertension	17
Thyroid dysfunction following pregnancy and implications for breastfeeding	16
New types of localization methods for adrenocorticotropic hormone-dependent Cushing’s syndrome	16
Diagnosis and management of premature ovarian insufficiency	16
Management of neonates born to mothers with thyroid dysfunction, and points for attention during pregnancy	16
Next-generation therapeutic bacteria for treatment of obesity, diabetes, and other endocrine diseases	16
Androgens and male sexual function	15
Management of adrenal incidentalomas: Working through uncertainty	15
Prenatal exposure to phthalate esters and its impact on child development	15
Quality of life in Cushing’s syndrome	15
Interpretation of thyroid function tests during pregnancy	15
Cognitive health after menopause: Does menopausal hormone therapy affect it?	15
Genetics of 46,XY gonadal dysgenesis	14
Genetics of cryptorchidism and testicular regression	14
Marrow adipogenic lineage precursor: A new cellular component of marrow adipose tissue	14
Genetics of anti-Müllerian hormone and its signaling pathway	14
Steroid profiling in the diagnosis of mild and overt Cushing’s syndrome	14
Infertility considerations in klinefelter syndrome: From origin to management	13
Hormone therapy and cardiovascular disease: Benefits and harms	13

Biochemical diagnosis of Cushing’s disease: Screening and confirmatory testing	13
Gut microbiota and their metabolites in cardiovascular disease	13
Primary polydipsia: Update	12
Cushing syndrome: Old and new genes	12
Neural regulation of bone marrow adipose tissue	12
Regulation of bone mass in inflammatory diseases	12
Paraneoplastic autoimmune hypophysitis: An emerging concept	12
COVID-19 vaccination and thyroiditis	12
Haematological actions of androgens	12
Auto-immunity and the gut microbiome in type 1 diabetes: Lessons from rodent and human studies	12
Hypercoagulability in Cushing’s syndrome: From arterial to venous disease	11
Statins and diabetes: What are the connections?	11
Menopausal hormone therapy in women with medical conditions	11
Clinical imaging of marrow adiposity	11
The definition of remission and recurrence of Cushing’s disease	11
Anaplastic thyroid cancer: An update	11
Pathophysiology of thyroid-associated orbitopathy	11
Primary aldosteronism: Treatment of the disease, and new therapeutic approaches	10
Immune checkpoint inhibitor-related hypophysitis	10
Old and new genes in primary aldosteronism	10
Assessment of mild autonomous cortisol secretion among incidentally discovered adrenal masses	10
Primary hyperparathyroidism	10
Updates in the outcomes of radiation therapy for Cushing’s disease	10
Ageing male (part I): Pathophysiology and diagnosis of functional hypogonadism	10
Second line treatment of acromegaly: Pasireotide or Pegvisomant?	10
Endocrine immune-related adverse events: Adrenal, parathyroid, diabetes insipidus, and lipoatrophy	10
Cushing's syndrome – Disease monitoring: Recurrence, surveillance with biomarkers or imaging studies	10
Disease monitoring of patients with pheochromocytoma or paraganglioma by biomarkers and imaging studies	10
Kallman syndrome and central non-obstructive azoospermia	9
Exercise and physical activity in individuals at risk of fracture	9
The role of hormone therapy in urogenital health after menopause	9
Congenital disorders of estrogen biosynthesis and action	9
Epigenetic regulation of bone mass	9
Thyroid nodules and cancer during pregnancy, post-partum and preconception planning: Addressing the uncertainties and challenges	9
Management of overt hypothyroidism during pregnancy	9
Differentiated thyroid carcinoma: An update	9
Clinical implications of Y chromosome microdeletions among infertile men	8
Angiopoietin-like 3: An important protein in regulating lipoprotein levels	8
Medullary thyroid cancer - An update	8
Genetic forms of neurohypophyseal diabetes insipidus	8
In utero exposure to phthalates and reproductive toxicity in rodents	8
Endocrine-disrupting chemicals and behaviour: A high risk to take?	8
Temozolomide in aggressive pituitary tumours and pituitary carcinomas	8
Immunotherapy in pituitary carcinomas and aggressive pituitary tumors	8
Pediatric thyroid cancer: Recent developments	8
Medical therapy in severe hypercortisolism	8
Preclinical models for investigating how bone marrow adipocytes influence bone and hematopoietic cellularity	8
Bone marrow adipocytes – Good, bad, or just different?	7
Type 1 diabetes related to immune checkpoint inhibitors	7
Sperm genetic abnormalities and their contribution to embryo aneuploidy & miscarriage	7
What is the role of medical therapy in adrenal-dependent Cushing's syndrome?	7
Molecular testing in thyroid cancer diagnosis and management	7
Remnant lipoprotein particles and cardiovascular disease risk	7
SARS-CoV-2 infection and its effects on the endocrine system	7
Active surveillance of low-risk papillary thyroid microcarcinoma	7
Genetics of pubertal timing	7
Endocrine abnormality in paraneoplastic syndrome	6
Genetic variants of gonadotrophins and their receptors: Impact on the diagnosis and management of the infertile patient	6
Chemokines in thyroid autoimmunity	6
Genetics of congenital central hypogonadism	6
Faecal microbiota transplantation in endocrine diseases and obesity	6
The effect of osteoporosis treatment on bone mass	6
COVID-19 and metabolic syndrome	6
Pituitary and SARS CoV-2: An unremitting conundrum	6
Genomic and epigenomic profile of thyroid cancer	6
Innovative therapeutics in acromegaly	6
COVID-induced thyroid autoimmunity	6
Thyroid autoimmunity and pregnancy in euthyroid women	6
Androgens, sports, and detection strategies for anabolic drug use	5
The role of reoperation after recurrence of Cushing’s disease	5
Common symptoms associated with usage and cessation of anabolic androgenic steroids in men	5
Universal screening for thyroid disease SHOULD NOT be recommended before and during pregnancy	5
Accurate measurement of total and free testosterone levels for the diagnosis of androgen disorders	5
Role of sex steroids hormones in the regulation of bone metabolism in men: Evidence from clinical studies	5
Effects of endocrine disorders on lipids and lipoproteins	5